Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.

Abstract

Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease -a potentially harmful practice.

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

“…Dear Editor, we have read with interest the comments to our article [1] by Prentice et al [2] . The authors mainly underlined the potential harms associated with asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in IBD patients without a strong evidence base to dictate subsequent practice on the return of a positive test .…”